The application period for the immunoglobulin Palivizumab, for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV). The expensive drug is intended for patients under the age of 2 who reside or are hospitalized in Cuiabá. The application takes place at the Urgent Care Unit (UPA) of Verdão.
The criteria for requesting the application of the immunoglobulin Palivizumab are:
– Children born with a gestational age less than or equal to 28 weeks (up to 28 weeks and 6 days) aged less than 1 year (up to 11 months and 29 days) or
– Children under 2 years of age (up to 1 year, 11 months and 29 days) with chronic pneumonitis of prematurity, bronchopulmonary dysplasia or congenital heart disease with proven haemodynamic repercussions.
period of application immunoglobulin
The supply and application period includes the months of greatest circulation of the respiratory syncytial virus (RSV), which, according to studies by the Ministry of Health, occurs from March to July, in the Brazilian Midwest. The technical manager Sônia Maria do Carmo Nabarrete explains that since the purpose of the drug is to prevent the onset of respiratory diseases such as, for example, bronchiolitis, the start of the application takes place one month before the seasonality, that is say in February. Each child can receive up to five applications, depending on date of birth and entry into the application process.
To request the drug Palivizumab with reference to the mentioned seasonality, the person responsible for the child must present a copy of the birth certificate, SUS card and proof of residence; current medical prescription; in addition to medical reports specifying the need to use this drug.
In the case of premature patients, it is also necessary to attach a copy of the hospital discharge report.
In the case of patients with congenital heart disease with proven haemodynamic repercussions, it is necessary to attach, in addition to the personal documents and the medical prescription, a copy of the medical report with the description of the heart disease, the degree of pulmonary hypertension and medications used, and a copy of last year’s echocardiography report.
According to the Brazilian Immunization Society (SBIm), palivizumab is not a vaccine, but an immunoglobulin – a “ready-to-use” type of antibody, prepared by a genetic engineering technique – which induces passive immunization. specific against respiratory syncytial virus (RSV). ). Currently, it is the only form available for the prevention of serious cases of respiratory infections in infants, such as bronchiolitis and, mainly, pneumonia.
To read also in Mato Grosso: